SCYX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCYX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. SCYNEXIS's selling, general, & admin. expense for the three months ended in Mar. 2024 was $3.7 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $19.7 Mil.
The historical data trend for SCYNEXIS's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Selling, General, & Admin. Expense | Get a 7-Day Free Trial |
![]() |
![]() |
10.65 | 14.63 | 49.92 | 62.96 | 20.92 |
SCYNEXIS Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Selling, General, & Admin. Expense | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
4.84 | 7.47 | 5.01 | 3.59 | 3.67 |
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Selling, General, & Admin. Expense falls into.
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (NAS:SCYX) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Thank you for viewing the detailed overview of SCYNEXIS's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
David C Hastings | director | C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
Brian Philippe Tinmouth | director | 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548 |
Guy Macdonald | director | C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139 |
Ann Hanham | director | ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Armando Anido | director | 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
Ivor Macleod | officer: Chief Financial Officer | 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634 |
Scott Sukenick | officer: General Counsel | 101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302 |
Marco Taglietti | director | C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
Lawrence R Hoffman | officer: Interim CFO | C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087 |
Christine Coyne | officer: Chief Commercial Officer | 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Eric Francois | officer: Chief Financial Officer | C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713 |
Gonzalez David Angulo | officer: Chief Medical Officer | C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713 |
From GuruFocus
By PRNewswire • 11-29-2023
By PRNewswire • 01-04-2024
By PRNewswire • 01-06-2024
By PRNewswire • 01-08-2024
By ACCESSWIRE • 11-22-2023
By PRNewswire • 11-29-2023
By PRNewswire • 12-15-2023
By PRNewswire • 12-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.